The ASCO Post

@ASCOPost · Huntington, NY · joined 15 Dec 2009

News and views from the world of clinical oncology and hematology

62 531Followers

4 489Following

35 351Posts total

5.6KViews on collected posts

Последние посты

The ASCO Post@ASCOPost15 Sep

🖥️ #ASCOAI: AI-based TIL scoring may offer a scalable prognostic tool in #BreastCancer, particularly where expert pathologist assessment is limited. Two studies evaluated computational approaches in triple-negative and HER2+ disease. 🔗 https://t.co/kVgVg6NjJB https://t.co/DKPn

768 views · 3 likes · 2 reposts · 1 replies Open on X →

The ASCO Post@ASCOPost15 Sep

💉Could less frequent tarlatamab dosing offer flexibility in #SCLC? In DeLLphi-309, 20 mg every 3 weeks and 30 mg every 4 weeks showed efficacy and safety consistent with the approved every-2-week regimen. 🗣️ Presented by Jonathan Goldman, MD at #WCLC26 🔗 https://t.co/qUkXCv082g h

1.3K views · 14 likes · 4 reposts · 1 replies Open on X →

The ASCO Post@ASCOPost15 Sep

💊 Cancer centers continue to navigate medication shortages. @NCCN reports 61% of responding centers required pharmacy- and physician-led mitigation strategies to keep patients on recommended doses and schedules. Learn more about the survey results 👉 https://t.co/VDvSJRRK6H ht

689 views · 1 likes · 1 reposts · 2 replies Open on X →

The ASCO Post@ASCOPost15 Sep

🫁 Phase 3️⃣ IMpower030: Perioperative atezolizumab + platinum chemo yielded a median event-free survival of 62.8 vs 34.9 months with chemotherapy alone in patients with resectable stage IIB–IIIB #NSCLC. 🗣️Presented by Benjamin Solomon, MD at #WCLC26 🔗 https://t.co/Pt9gFWgLQz

1.1K views · 6 likes · 4 reposts · 0 replies Open on X →

The ASCO Post@ASCOPost14 Sep

🆕 research suggests inherited genetics may help classify therapy-related #myeloidneoplasms and identify patients who could benefit from personalized risk assessment, genetic counseling & closer monitoring. 🔹Francesc Solé, PhD (@SoleKiko | @BloodAdvances https://t.co/5N928PuvnP h

1K views · 1 likes · 0 reposts · 0 replies Open on X →

The ASCO Post@ASCOPost11 Sep

🏥 #ASCOAI: As #AI reshapes #cancercare, patients must remain at the center. @jamecancerdoc of @ClevelandClinic discusses why AI’s potential should be measured by whether it can expand access to affordable, high-quality care. Watch the video ➡️ https://t.co/a0xUTBZGIy https://

731 views · 1 likes · 0 reposts · 0 replies Open on X →

На фоне аккаунтов своего размера

6 постов за последние 90 дней рядом с диапазоном 10K–100K подписчиков. ниже своих по обоим показателям — и по охвату, и по отклику.

Медианные просмотры886этот аккаунт924медиана для 10K–100K

Охват, %1.42%этот аккаунт3.62%медиана для 10K–100K

Вовлечённость, %0.68%этот аккаунт1.52%медиана для 10K–100K

Показатель	Этот аккаунт	Медиана для 10K–100K	Отношение
Медианные просмотры на пост	886	924	0.96×
Охват (просмотры ÷ подписчики)	1.42%	3.62%	0.39×
Вовлечённость	0.68%	1.52%	0.45×

Другие в этом диапазоне → Сравнить с другим аккаунтом → Как считаются эти ориентиры →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

73111 Sep

1K14 Sep

1.1K15 Sep

689

1.3K

768

Last 6 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.14%11 Sep

0.10%14 Sep

0.91%15 Sep

0.58%

1.56%

0.78%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes53.1%26 in total

Reposts22.4%11 in total

Replies8.2%4 in total

Quotes2.0%1 in total

Bookmarks14.3%7 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

Followers by day

12 Sep

Daily snapshots since 12 Sep 2026; the dashed line is the starting count.

Последние посты

На фоне аккаунтов своего размера

Growth & engagement

Views per post

Engagement rate per post

What the audience does

Followers by day

Похожие аккаунты